Positive Trial Data for AstraZeneca Lung Cancer Immunotherapy Sets the Stage for Battle with Merck’s Keytruda

March 10, 2023

AstraZeneca

Astrazeneca reported promising data for its non-small cell lung cancer (NSCLC) immunotherapy Imfinzi, setting the stage for a market showdown with Merk’s Keytruda. The therapy, when added to chemotherapy, improved event-free survival in patients undergoing surgery for early stage NSCLC. Once entering the market, the drug is set to be a strong competitor with Keytruda.

According to Angus Liu, “AZ’s Imfinzi win comes only days after Merck & Co.’s immuno-oncology leader Keytruda claimed its own event-free survival win in resectable early-stage NSCLC. In the Keynote-671 study, Keytruda was tested as a neoadjuvant therapy and as an adjuvant therapy around surgery. With the dueling wins, doctors and analysts will surely compare data from Imfinzi’s Aegean and Keytruda’s Keynote-671 trials side by side. For now, patient survival data remain immature for both regimens.”

To read more, click here.

(Source: Fierce Pharma, March 9th, 2023)

Share This Story!